Screener / SEC EDGAR /CIK 0001178670 /10-K filed Feb 12, 2026, compared with Feb 13, 2025 /Numbers from the XBRL of the 10-Ks
Nasdaq Health care · Pharmaceuticals

Alnylam Pharmaceuticals, Inc. ALNY

Compare with peers Embed
SEC comment letters, last 20 years

4 reviews of ALNY's filings by SEC staff

UPLOAD and CORRESP
Reviews 4 latest letter May 9, 2025
Questions asked 5 each answered in the company's own letter
No closing letter 0 reviews without a letter saying the staff completed it

When the SEC's staff reviews a filing, it writes to the company with numbered questions, and the company answers each one in a letter. SEC publishes the exchange once the review is over, at least 20 business days later. A question is not an accusation; most reviews end with the company adding detail to its next filing.

How the reviews went

Every review on EDGAR, from the first staff letter to the letter that closes it

  1. 1. Staff letters 5 UPLOAD
  2. 2. Questions in them 5 numbered comments
  3. 3. Company replies 5 CORRESP
  4. 4. Reviews closed 4 of 4 closing letter

Half the closed reviews took 44 days or less from the first letter to the closing letter.

Form 10-K for the fiscal year ended December 31, 2024

2025-05-09 to 2025-06-17 · 1 question · 1 letter from the SEC, 1 from the company
Review closed 2025-06-17
RevenueResults discussion (MD&A)
Notes to Consolidated Financial Statements
SEC asked
Net Revenues from Collaborations Regeneron Pharmaceuticals, Inc., page 105 Please link revenue recognized under the Regeneron collaboration and associated deferred revenue on page 108 to corresponding amounts reported in the financial statements for each period presented. Revise your disclosure accordingly.
Rest of the question

In addition, provide the following information related to your accounting treatment for the June 2024 Amendment. • Explain why the transaction price allocated to the new C5 Monotherapy Obligation was recognized at a point in time, while the transaction price allocated to the legacy C5 License Obligation is recognized over time, given your apparent continuing obligations to support these two licenses. Describe and quantify key assumptions underlying your determination of • 1. standalone selling price of $322,000 for the C5 Monotherapy Obligation, including discount rates, forecasted earnings, duration of the commercial period and adjustments for probability of success. • Explain how you determined revenue recognized in 2024 for the Research Services Obligation and C5 License Obligation, particularly expected performance periods, and why no revenue was recognized for the Regeneron Technology Transfer Obligation. • Demonstrate that the cumulative catch up adjustment for the remaining Research Services Obligation and C5 License Obligation was not significant. In closing, we remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.

ALNY answered
Revenue recognized under the Regeneron collaboration is presented in net revenues from collaborations in the consolidated statements of operations and comprehensive loss and the associated deferred revenue is presented within deferred revenue and deferred revenue, net of current portion in the consolidated balance sheets.

The composition of net revenues from collaborations in the consolidated statements of operations and comprehensive loss, as disclosed in Note 4 of the Form 10-K (page 102), is as follows:

(in thousands) Years ended December 31,

2024 2023

2022

Roche $ 119,489 $ 337,802 $
Rest of the answer

—

Regeneron Pharmaceuticals 302,798 100,468 87,844

Novartis AG 79,759 86,727 43,159

Other 8,175 21,188 3,909

Total net revenues from collaborations $ 510,221 $ 546,185 $ 134,912

In addition, also in Note 4 the Company disclosed additional detail on revenue recognized from the Regeneron collaboration as follows:

Research Services Obligation (as presented on page 108) $ 39,097 $ 80,200 $ 28,600

C5 License Obligation (as presented on page 108) 38,341 (15,100) 32,500

C5 Monotherapy Obligation (as discussed on page 107) 191,520 — —

C5 Co-Co Obligation (recognized prior to June 2024 Amendment)1

700 7,400 20,080

Other license programs2

33,140 27,968 6,664

Total $ 302,798 $ 100,468 $ 87,844

1Revenue recognized for the C5 Co-Co Obligation is not separately disclosed because the disclosure on page 108 provides a summary of revenue recognized during the period for the remaining unsatisfied performance obligations as of the balance sheet date in accordance with ASC 606-10-50-8. In June 2024, the C5 Co-Co Collaboration Agreement was terminated. Therefore, the Company's obligation under the C5 Co-Co performance obligation ended prior to and is no longer unsatisfied as of December 31, 2024.

2 Revenue recognized for the “Other license programs” relates to seven separate programs subject to individual license agreements with Regeneron that are not material for separate disclosure.

The composition of deferred revenue and deferred revenue, net of current portion as presented in the consolidated balance sheet as of December 31, 2024 is as follows:

(in thousands) Current Non-current Total

Research Services Obligation $ 41,155 $ — $ 41,155

C5 License Obligation 12,018 — 12,018

Regeneron Technology Transfer Obligation 2,307 — 2,307

Rounding difference

1 — 1

Total $ 55,481 $ — $ 55,481

The composition of deferred revenue and deferred revenue, net of current portion as presented in the consolidated balance sheet as of December 31, 2023 is as follows:

Research Services Obligation $ 61,500 $ 1,900 $ 63,400

C5 License Obligation 27,500 — 27,500

C5 Co-Co Obligation — 186,200 186,200

Other deferred revenue3

13,663 — 13,663

Total4

$ 102,663 $ 188,100 $ 290,763

3 “Other deferred revenue” does not relate to our arrangements with Regeneron. This amount represents our obligation to deliver products and/or provide services to other parties.

4The difference between the "Total" amounts in the table above and the consolidated balance sheet is related to deferred product revenues.

Two of the Company's remaining performance obligations as of December 31, 2024 (that is, the C5 License Obligation and Regeneron Technology Transfer Obligation) were completed in the first quarter of 2025. The Company will enhance its disclosure in future filings, starting with the Form 10-Q for the threeand six-month periods ending June 30, 2025, as it relates to revenue recognized from the Company's arrangements with Regeneron. The disclosure will also include a statement that revenue earned from these arrangements is presented in net revenues from collaborations in the consolidated statements of operations and comprehensive loss and the remaining deferred revenue is presented within deferred revenue in the consolidated balance sheets. To enhance its disclosures in future Form 10-K filings, the Company plans to replace the tables that were included in its Form 10-K with the tables presented in Appendix A. The Company also plans to include similar tables to supplement the disclosures in its Form 10-Q filings, beginning with its Form 10-Q for the threeand six-month periods ending June 30, 2025.

In addition, provide the following information related to your accounting treatment for the June 2024 Amendment.

•Explain why the transaction price allocated to the new C5 Monotherapy Obligation was recognized at a point in time, while the transaction price allocated to the legacy C5 License Obligation is recognized over time, given your apparent continuing obligations to support these two licenses.

Response

Legacy C5 License Obligation

The legacy C5 License Agreement from 2019 previously provided Regeneron with rights to the Company's cemdisiran product candidate solely to be used in combination with pozelimab, Regeneron’s drug candidate. Regeneron is responsible for the development and commercialization of cemdisiran to be used in combination with pozelimab. The Company's obligations included granting Regeneron a worldwide license to cemdisiran for combination therapies, manufacturing and supply and development services.

When the Company entered into the C5 License Agreement in 2019, it concluded, in accordance with ASC 606-10-25-19, that the worldwide license to cemdisiran for combination therapeutics is not capable of being distinct nor distinct within the context of the contract as Regeneron could not benefit from the license on its own or with other readily available resources. At the time this arrangement was executed, RNAi technology was a new technology and contract development and manufacturing organizations did not have the technical expertise and know-how to support the manufacturing process related to RNAi technology. Given the early-stage nature of the intellectual property, and highly specialized and new nature of RNAi technology, no one other than the Company could perform the manufacturing and supply services. The Company also expected that the development services performed by it would involve significant modification to the intellectual property. Therefore, the Company concluded that the license was not distinct from the manufacturing and supply services or the development services.

The Company combined the license to cemdisiran for combination therapies, as well as the manufacturing and supply and development services obligations into one performance obligation which the Company refers to as the C5 License Obligation. The Company measures proportional performance for the C5 License Obligation over time using an input method based on cost incurred relative to the total expected costs to be incurred to determine the proportion of effort incurred as a percentage of the total effort the Company expects to expend. This ratio is applied to the transaction price for the C5 License Obligation to determine the amount of revenue to recognize. Pursuant to ASC 606-10-25-35, as circumstances change over time, the Company updates its measure of progress to reflect any changes in the outcome of the performance obligation.

The June 2024 Amendment did not change the Company's legacy C5 License Obligation. The Company's C5 License Obligation was partially satisfied at the time of the contract modification, and the Company remained obligated to provide manufacturing and supply and development services for cemdisiran as a combination therapy to Regeneron. As the Company's C5 License Obligation was only partially satisfied at the time of the contract modification, the Company continues to recognize revenue over time using the input-based method described above. The Company recorded a cumulative catch-up at the time of the contract modification, which is discussed below in more detail.

C5 Monotherapy Obligation

In 2024, the C5 Co-Co Collaboration Agreement related to cemdisiran as a monotherapy was terminated, and at the same time the Company granted Regeneron a worldwide license to cemdisiran as a monotherapy. Regeneron is now fully responsible for the development, manufacturing and commercialization of cemdisiran as a monotherapy. By granting Regeneron a worldwide license to cemdisiran as a monotherapy, the Company transferred new rights to the cemdisiran monotherapy intellectual property to Regeneron. The Company no longer had any future obligations to perform development, manufacturing and commercialization activities for cemdisiran as a monotherapy.

The Company concluded, in accordance with ASC 606-10-25-19, that the license to develop, manufacture and commercialize cemdisiran as a monotherapy is a distinct good. As a global, mature, fully integrated biopharmaceutical company, Regeneron has the ability on its own or with the use of readily available resources to generate economic benefit from the license. The manufacturing process to produce cemdisiran is no longer unique, specialized or requires the Company’s expertise and knowledge in order to benefit from the license, as it did in 2019. Over the last five years, there has been substantial advancement in RNAi technologies, including the commercialization of multiple products to treat disease using RNAi technology and a significant number of companies using this technology to identify new medicines. Additionally, contract development and manufacturing organizations have gained technical expertise and know-how to support the manufacturing process related to RNAi technology.

At the transfer of control of the license in June 2024, Regeneron has the knowledge and expertise as well as the development, manufacturing and commercial processes in place to generate economic benefit from the license. Regeneron can begin to use and benefit from the license at this time and Regeneron also has the right to sublicense the intellectual property, which gives the license standalone value for which Regeneron can benefit from the license on its own. Therefore, the transaction price of $191.5 million allocated to the C5 Monotherapy Obligation was recognized immediately as this obligation was satisfied at a point in time upon transfer of the license to Regeneron.

•Describe and quantify key assumptions underlying your determination of standalone selling price of $322,000 [sic] for the C5 Monotherapy Obligation, including discount rates, forecasted earnings, duration of the commercial period and adjustments for probability of success.

Response

The Company developed the estimated standalone selling price of $332,000 for the cemdisiran monotherapy license granted under the C5 Monotherapy Obligation using the adjusted market assessment approach based on a discounted cash flow model that establishes the forecasted earnings during the commercial period for cemdisiran as a monotherapy adjusted for probability of success. The key assumptions underlying our determination of the standalone selling price are (all dollar amounts below are presented in thousands):

•Revenue – The Company's discounted cash flow model starts in [***] and continues until [***]. The last cemdisiran monotherapy patent expires in [***]. The substantial majority of the revenue from cemdisiran as a monotherapy is estimated to occur between [***]. The Company believes that cemdisiran as a monotherapy will continue to [***]. The range of annual revenue is [***] until [***], to a peak of [***].

•Probability of Success - The Company incorporated a cumulative phase of outcome probability of success of [***], consistent with our and industry established standards, given the current stage of development for cemdisiran as a monotherapy. At the time of the contract modification, cemdisiran was in the second phase of clinical development. The Company considered a [***] likelihood of a successful outcome of cemdisiran in the third phase of clinical development and a [***] likelihood of cemdisiran receiving regulatory approval if the second and third phase of the clinical development process are successful. In other words, the [***] probability of success represents [***] of the [***] chance of a successful outcome of cemdisiran in the third phase of clinical development.

•Research and Development Expense – The Company estimated research and development expenses based on the expected costs to be incurred to complete the clinical development process and any open label expansion trials for cemdisiran as a monotherapy.

•Other Operating Expenses – Other operating expenses primarily represent commercial expenses and general and administrative expenses. The Company estimated these expenses as a consistent percentage of revenue based on our historical experience with other commercial products.

•Discount rate – The Company utilized a discount rate of [***] which was determined based on an estimated market participant weighted average cost of capital.

•Explain how you determined revenue recognized in 2024 for the Research Services Obligation and C5 License Obligation, particularly expected performance periods, and why no revenue was recognized for the Regeneron Technology Transfer Obligation.

Response

For the Research Services Obligation and the legacy C5 License Obligation the Company measured proportional performance over time using an input-based method based on costs incurred (the numerator in the cost-to-cost model) relative to the total expected costs to be incurred (the denominator in the cost-to-cost model) to determine the proportion of effort incurred as a percentage of total effort the Company expects to expend. This ratio is applied to the transaction price allocated to each obligation to determine the amount of revenue to recognize. Pursuant to ASC 606-10-25-35, as circumstances change over time, the Company updates its measure of progress to reflect any changes in the outcome of the performance obligation.

The expected performance period for the Research Services Obligation aligns with the research term which has been agreed to with Regeneron. As of December 31, 2024, the deferred revenue related to the Research Services Obligation was expected to be recognized within the next twelve months.

The expected performance period of the C5 License Obligation aligns with a manufacturing and development schedule agreed to with Regeneron. As of December 31, 2024, the C5 License Obligation was expected to be completed within the next twelve months. The C5 License Obligation was completed in the three months ended March 31, 2025.

No revenue was recognized for the Regeneron Technology Transfer Obligation in 2024 because the Company did not start performing these technology transfer services until 2025. This technology transfer to Regeneron was started and completed during the three months ended March 31, 2025.

•Demonstrate that the cumulative catch up adjustment for the remaining Research Services Obligation and C5 License Obligation was not significant.

Response

The cumulative catch-up adjustment was a decrease of $2.5 million for the Research Services Obligation and an increase of $1.5 million for the C5 License Obligation, as calculated below. These amounts were not considered to be quantitatively significant to the Company’s consolidated financial statements.

Read in the reply

Also in this review: closing letter, 2025-06-17

Form 10-K for the Fiscal Year Ended December 31, 2023

2024-08-12 to 2024-09-25 · 1 question · 1 letter from the SEC, 1 from the company
Review closed 2024-09-25
Revenue
Notes to Consolidated Financial Statements
SEC asked
Net Revenues from Collaborations, page 107 1. We note your tabular disclosure at the bottom of page 107 that quantifies the research and development (R&D) expenses incurred by collaborator and type that are directly attributable to your collaboration agreements. Please explain to us how this disclosure relates to your net revenues from collaborations.
Rest of the question

Using the Roche collaboration as an example, your disclosure on page 110 indicates that you recognized collaboration revenue of $24 million during 2023 related to your Development Services Obligation. Please explain how this amount relates to the $44.6 million in total R&D expenses attributed to the Roche collaboration as disclosed on page 107. In addition, to the extent applicable, please explain how the $547 million additional variable consideration attributed to cost reimbursement from development and manufacturing services and technology transfer related to the Roche Performance Obligations was calculated. 2. Please explain the circumstances that resulted in a reversal of revenue in the amount of $15.5 million related to your Regeneron C5 License Obligation during 2023 as disclosed on page 113.

ALNY answered
#1:

The table at the bottom of page 107 discloses the type and amount of research and development (“R&D”) expenses incurred for the Company's collaborations. Each of our collaboration agreements has unique performance obligations and cost sharing mechanisms. For our collaboration with Regeneron Pharmaceuticals, Inc. (“Regeneron”), revenue is recognized on a cost-to-cost input method and the costs used to measure both costs incurred and total costs are only those that relate to these performance obligations. Under the Company’s Collaboration and License Agreement with F.
Rest of the answer

Hoffmann-La Roche Ltd. and Genentech, Inc. (together, “Roche”), dated as of July 21, 2023 (the “Roche Agreement”), we are reimbursed based on a percentage of the cost related to the R&D performance obligation. As requested by the Staff, we explain this in more detail below using our collaboration with Roche as an example.

Roche

Under the Roche Agreement, the Company has a performance obligation under Accounting Standards Codification (“ASC”) 606 and is obligated to perform development services, including the manufacture of clinical supply to support the regulatory approval of zilebesiran (the “Roche Development Services Obligation”). The Company is responsible for 40% and Roche is responsible for 60% of the costs incurred to perform the Roche Development Services Obligation.

At inception of the Roche Agreement, based on the development plan agreed to by the Company and Roche (the “Development Plan”), the Company was able to estimate the development activities it will perform under the Roche Development Services Obligation and the reimbursement that it is entitled to receive from Roche. The Company used the expected value method and estimated the expected value amount as $545 million. The estimated expected value amount represents 60% of the total cost (the Roche share) per the Development Plan based on the hours and costs expected to be incurred to perform all of the development activities until commercialization, risk adjusted based on the probability of successful completion of all of the phases which are contingent upon future regulatory events. The Company concluded it is probable that a significant reversal of cumulative revenue will not occur in the future if some amount of the variable payments are not ultimately paid, because the cost reimbursement amounts are only recognized as revenue as the Company performs the development activities under the Roche Development Services Obligation.

During the year ended December 31, 2023, the Company incurred $45 million in R&D expenses related to the Roche collaboration and recognized collaboration revenue of $24 million related to the Roche Development Services Obligation. Of the $45 million in R&D expenses incurred, approximately $40 million related to the Roche Development Services Obligation.

The Company recognizes the consideration associated with the Roche Development Services Obligation using the cost-to-cost method which is based on cost incurred (the numerator in the cost-to-cost model) relative to the total estimated cost of the obligation (the denominator in the cost-to-cost-model) to determine the proportion of effort incurred as a percentage of total effort the Company expects to expend. This ratio is applied to the transaction price allocated to the obligation. As of December 31, 2023, the Company is approximately 4% complete with the Roche Development Services Obligation and has recognized $24 million of the $545 million transaction price associated with this obligation.

As all costs in the cost-to-cost model are allowable for reimbursement from Roche, and the assumptions used to determine the total estimated cost of the obligation (denominator in the cost-to-cost model) are consistent with the assumptions used to determine the transaction price associated with the obligation, the collaboration revenue recognized will approximate 60% of the actual reimbursable costs incurred.

Therefore, $24 million of collaboration revenue recognized under the cost-to-cost model can also be calculated as the $40 million of R&D expenses related to the Roche Development Services, multiplied by 60%, which is the Company’s reimbursement amount from Roche.

The Company also has an obligation to perform a technology transfer of the existing manufacturing process for zilebesiran (the “Roche Technology Transfer Obligation”). The Company used the expected value method to estimate the expected value amount of $2 million based on the estimated costs expected to be incurred to perform the technology transfer activities. The Company did not recognize any collaboration revenue for the Roche Technology Transfer Obligation in the year ended December 31, 2023.

Regeneron

The Company recognizes revenue related to its collaboration with Regeneron over time using an input-based method on costs incurred relative to the total expected costs to be incurred for each of the identified performance obligations (“percentage of completion”). The specific amount of collaboration revenue for the period is determined by applying the percentage of completion to the transaction price allocated to each performance obligation. Hence, the R&D costs disclosed in the table on page 107 determine the extent of progress toward completion of the R&D services, but our collaboration revenue is based on the consideration allocated to the performance obligation.

2.Please explain the circumstances that resulted in a reversal of revenue in the amount of $15.5 million related to your Regeneron C5 License Obligation during 2023 as disclosed on page 113.

Response to Comment #2:

During 2019, the Company entered into a global, strategic collaboration with Regeneron to discover, develop and commercialize RNAi therapeutics for a broad range of diseases. At the inception of the Regeneron collaboration, the Company identified an obligation to provide Regeneron with a worldwide license to cemdisiran for combination therapies, manufacturing and supply and development service obligations (the “C5 License Obligation”). The Company determined that the worldwide license to cemdisiran for combination therapies is not distinct from the manufacturing and supply and development service obligations as Regeneron cannot benefit on its own from the value of the license without receipt of the supply. Therefore, the C5 License Obligation is a single performance obligation.

The C5 License Obligation is satisfied over time using an input-based method based on costs incurred relative to the total expected costs to be incurred. The amount of revenue recognized during each period for the C5 License Obligation is impacted by changes in the percent complete for the period, which is driven by changes in either costs incurred to date (the numerator in the percentage calculation) or changes in total expected costs to be incurred (the denominator in the percentage calculation). Pursuant to ASC 606-10-25-35, as circumstances change over time, the Company updates its measure of progress to reflect any changes in the outcome of the performance obligation. Such changes to the Company’s measure of progress are accounted for as a change in accounting estimate.

During the fourth quarter of 2023, Regeneron increased the scope of the manufacturing and supply activities for the C5 License Obligation to support the potential future manufacturing of cemdisiran as a commercial drug. The Company assessed the facts and circumstances surrounding this change, which resulted from new information communicated by Regeneron, and determined that such change represents a change in estimate in the fourth quarter of 2023.

The total expected costs to be incurred to perform the C5 License Obligation increased in the fourth quarter of 2023 to reflect the additional hours and costs expected to be incurred by the Company to perform the manufacturing and supply activities. When completing the Company's periodic update to its estimated costs to complete and, in turn, the cumulative progress toward completion of the C5 License Obligation, the Company used its updated estimate of total expected costs to be incurred as the denominator in the cost-to-cost model and recalculated the cumulative amount of revenue that should be recognized. That cumulative amount of revenue is compared to the cumulative amount of revenue recognized as of the prior period end (December 31, 2022). As indicated in the table below, as the estimate of total expected costs to be incurred in the denominator increased, the percentage of completion and the cumulative amount of revenue recognized decreased, resulting in the reversal of revenue in the amount of $15.1 million.

(In thousands, except percentages) December 31, 2022 December 31, 2023 Reversal of revenue during the year ended December 31, 2023

Read in the reply

Also in this review: closing letter, 2024-09-25

Form 10-K for the Fiscal Year Ended December 31, 2016

2017-11-27 to 2018-01-23 · 2 questions · 2 letters from the SEC, 2 from the company
Review closed 2018-01-23
Results discussion (MD&A)
Form 10-K for the Year Ended December 31, 2016 · Notes to Consolidated Financial Statements
SEC asked
Significant Agreements , page 97 1. For each significant agreement, please provide us a schedule by type and amount of costs incurred included in research and development expenses for the years ended December 31, 2015 and 2016 and for the nine months ended September 30, 2017.
Rest of the question

Also provide us a similar schedule for general and administrative expenses or confirm that you have not incurred material general and administrative expenses related to your significant agreements.

ALNY answered
This letter is being furnished in response to the comments of the staff (the “Staff”) of the Securities and Exchange Commission (the “Commission”) in the Commission’s letter dated November 27, 2017 (the “Comment Letter”) to Michael P. Mason, Vice President of Finance and Treasurer of Alnylam Pharmaceuticals, Inc. (the “Company”), with respect to the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2016, and the documents incorporated by reference therein. The responses set forth below have been organized in the same manner in which the Commission’s comments and headings were organized in the Comment Letter.
Rest of the letter

Comment: Notes to the Consolidated Financial Statements – 3. Significant Agreements, page 97 For each significant agreement, please provide us a schedule by type and amount of costs incurred included in research and development expenses for the years ended December 31, 2015 and 2016 and for the nine months ended September 30, 2017. Also provide us a similar schedule for general and administrative expenses or confirm that you have not incurred material general and administrative expenses related to your significant agreements. The research and development costs incurred for each significant agreement during the periods referenced above primarily consist of costs incurred for external development and manufacturing services for which the Company is reimbursed and licensing payments made to the licensor. As noted in Part II, Item 7, “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” a significant portion of the Company’s research and development costs, including overhead and compensation and related costs, are not tracked by project as they benefit multiple projects or the Company’s technology platform. For the years ended December 31, 2015 and 2016 and the nine months ended September 30, 2017, the Company did not incur material general and administrative expenses related to its significant agreements. The Company has provided to the Staff, under separate cover and on a confidential and supplemental basis pursuant to Rule 12b-4 under the Securities Exchange Act of 1934, as amended, additional information requested in the Staff’s comment. The Company also has requested confidential treatment of this information pursuant to

One letter for all the questions, without numbered answers. Read the reply
Notes to Consolidated Financial Statements
SEC asked
Significant Agreements, page 97 1. We acknowledge the information provided in your response to our prior comment 1 of our November 27, 2017 comment letter. As required by ASC 730-20-50-1b, please confirm to us that you will disclose herein the costs incurred for each of your significant agreements.
Rest of the question

We would expect the amount disclosed to include the costs you provided in your response and your reasonable estimate of other costs incurred albeit for which you may not track separately for each agreement. In this regard, it would appear that a reasonable estimate would be attainable, given that you track hours incurred for the purpose of billing your counterparties. Finally, we believe additional disclosure in your research and development expense discussion of your MD&A of the nature and amount of research and development costs incurred related to your agreements would be informative.

ALNY answered
This letter is being furnished in response to the comments of the staff (the “Staff”) of the Securities and Exchange Commission (the “Commission”) in the Commission’s letter dated January 8, 2018 (the “Comment Letter”) to Michael P. Mason, Vice President of Finance and Treasurer of Alnylam Pharmaceuticals, Inc. (the “Company”), with respect to the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2016, and the documents incorporated by reference therein. The responses set forth below have been organized in the same manner in which the Commission’s comments and headings were organized in the Comment Letter.
Rest of the letter

Comment: Notes to the Consolidated Financial Statements – 3. Significant Agreements, page 97 We acknowledge the information provided in your response to our prior comment 1 of our November 27, 2017 comment letter. As required by ASC 730-20-50-1b, please confirm to us that you will disclose herein the costs incurred for each of your significant agreements. We would expect the amount disclosed to include the costs you provided in your response and your reasonable estimate of other costs incurred albeit for which you may not track separately for each agreement. In this regard, it would appear that a reasonable estimate would be attainable, given that you track hours incurred for the purpose of billing your counterparties. Finally, we believe additional disclosure in your research and development expense discussion of your MD&A of the nature and amount of research and development costs incurred related to your agreements would be informative. In future periodic filings, including the Form 10-K for the fiscal year ended December 31, 2017, the Company will revise its disclosure to disclose the costs incurred for each of the Company’s significant agreements, including the costs provided in the Company’s response letter dated December 11, 2017, and a reasonable estimate of other costs incurred, and the Company will include additional disclosure in the research and development expense discussion of MD&A of the nature and amount of research and development costs incurred related to its significant agreements.

One letter for all the questions, without numbered answers. Read the reply

Also in this review: closing letter, 2018-01-23

Form 10-K

2015-11-25 to 2015-12-23 · 1 question · 1 letter from the SEC, 1 from the company
Review closed 2015-12-23
Notes to Consolidated Financial Statements
SEC asked
Significant Agreements, page 114 1. In order to help us understand more fully how your collaborative arrangements impact your financial statements for each period presented, please provide us, in table format, the amounts by year and by line item included in your statements of operations attributable to transactions arising from collaborative arrangements between you and the other participants and third-parties.
Rest of the question

Please provide separate tables for each of your significant collaborative arrangements and for all of your collaborative arrangements in the aggregate (i.e. the significant arrangements and all other arrangements). Present separately amounts with other participants and third-parties that are netted in a financial statement line item. Refer to ASC 808.

ALNY answered

No numbered answer found in the reply. Read the reply ↗

Also in this review: closing letter, 2015-12-23

Letters without questions

Other letters

UPLOAD and CORRESP
1 other letter: notices that a filing will not be reviewed, requests to declare a registration effective, and the like
  • Mar 20, 2019 · SEC: review completed · Alnylam Pharmaceuticals, Inc. · Preliminary Proxy Statement on Schedule 14A · Filed...

From the SEC's correspondence on EDGAR: staff letters (form UPLOAD) and company letters (form CORRESP), 15 letters filed since 2015-11-25. Questions and answers are matched by their numbers; topics come from words in each question. The reports are compared word for word (same form, before the first SEC letter against the first report after the company's reply). No AI.

Sources

The SEC's correspondence on EDGAR: staff letters (form UPLOAD) and company letters (form CORRESP), matched question by question. No AI.

Also

Filings: the letters in the filing list.

Work with it

Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/ALNY/export.csv") into a cell.

Next in Owners and insiders:Insider trades
Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.